Amicus Therapeutics Inc [NASDAQ: FOLD] closed the trading session at $5.99 on 2025-07-31. The day’s price range saw the stock hit a low of $5.97, while the highest price level was $6.38.
The stocks have a year to date performance of -40.75 percent and weekly performance of -4.62 percent. The stock has been moved at -37.54 percent over the last six months. The stock has performed 2.57 percent around the most recent 30 days and changed -22.01 percent over the most recent 3-months.
If compared to the average trading volume of 5.00M shares, FOLD reached to a volume of 8279146 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $15.82 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 17, 2025. While these analysts kept the previous recommendation, Morgan Stanley dropped their target price from $17 to $12. The new note on the price target was released on December 13, 2024, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise to $18, while Jefferies analysts kept a Buy rating on FOLD stock.
The Price to Book ratio for the last quarter was 9.03, with the Price to Cash per share for the same quarter was set at 0.75. Price to Free Cash Flow for FOLD in the course of the last twelve months was 1145.66 with Quick ratio for the last quarter at 2.29.
FOLD stock trade performance evaluation
Amicus Therapeutics Inc [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.62. With this latest performance, FOLD shares gained by 2.57% in over the last four-week period, additionally sinking by -37.54% over the last 6 months – not to mention a drop of -36.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 46.51, with the RSI for the last a single of trading hit 0.27, and the three-weeks RSI is set at 0.26 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 6.07, while it was recorded at 6.09 for the last single week of trading, and 8.36 for the last 200 days.
Amicus Therapeutics Inc [FOLD]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Amicus Therapeutics Inc [FOLD] shares currently have an operating margin of 4.39% and a Gross Margin at 88.98%. Amicus Therapeutics Inc’s Net Margin is presently recorded at -6.67%.
Amicus Therapeutics Inc (FOLD) Capital Structure & Debt Analysis
According to recent financial data for Amicus Therapeutics Inc. ( FOLD), the Return on Equity (ROE) stands at -22.62%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -4.87%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Amicus Therapeutics Inc’s Return on Invested Capital (ROIC) is -5.96%, showcasing its effectiveness in deploying capital for earnings.
Amicus Therapeutics Inc (FOLD) Efficiency & Liquidity Metrics
Based on Amicus Therapeutics Inc’s (FOLD) latest financial statements, the Debt-to-Equity Ratio is 2.17%, indicating its reliance on debt financing relative to shareholder equity.
Amicus Therapeutics Inc (FOLD) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Amicus Therapeutics Inc. (FOLD) effectively leverages its workforce, generating an average of -$76352.71 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.21% and a Quick Ratio of 2.29%, indicating strong ability to cover short-term liabilities.
Amicus Therapeutics Inc [FOLD]: Institutional Ownership
There are presently around $103.30%, or 104.05%% of FOLD stock, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 28.59 million shares, which is approximately 9.4111%. PERCEPTIVE ADVISORS LLC, holding 28.06 million shares of the stock with an approximate value of $$278.33 million in FOLD stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$271.81 million in FOLD stock with ownership which is approximately 9.0199%.
